Lyra Therapeutics, Inc.

NasdaqGM:LYRA Voorraadrapport

Marktkapitalisatie: US$17.0m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Lyra Therapeutics Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Maria Palasis

Algemeen directeur

US$1.8m

Totale compensatie

Percentage CEO-salaris32.7%
Dienstverband CEO9.8yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn2.2yrs
Gemiddelde ambtstermijn bestuur4yrs

Recente managementupdates

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Jul 05

Lyra Therapeutics: Progress In The Clinic

May 18

A First Look At Lyra Therapeutics

Apr 21

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04
We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05
How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11
Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

Analyse CEO-vergoeding

Hoe is Maria Palasis's beloning veranderd ten opzichte van Lyra Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$101m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$2mUS$583k

-US$63m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$61m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$583k

-US$55m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$48m

Dec 31 2021US$2mUS$552k

-US$44m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$4mUS$471k

-US$22m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$843kUS$388k

-US$17m

Compensatie versus markt: De totale vergoeding ($USD 1.79M ) Maria } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Maria is gestegen terwijl het bedrijf verliesgevend is.

CEO

Maria Palasis (59 yo)

9.8yrs

Tenure

US$1,785,375

Compensatie

Dr. Maria Palasis, Ph D, serves as Director at PanTher Therapeutics, Inc. since June 2021. Dr. Palasis has been Chief Executive Officer, President and Director of Lyra Therapeutics, Inc. since January 2015...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Harlan Waksal
Executive Chairman2.7yrsUS$625.06k0.40%
$ 67.8k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79mgeen gegevens
Carmichael Roberts
Co-Founderno datageen gegevensgeen gegevens
Jason Cavalier
CFO, Treasurer & Secretary3.1yrsUS$1.07mgeen gegevens
Ray Knox
Vice President of Operationsno datageen gegevensgeen gegevens
Ronan O'Brien
Chief Legal Officerless than a yeargeen gegevensgeen gegevens
Vineeta Belanger
Senior Vice President of Clinical Affairsno datageen gegevensgeen gegevens
Robert Richard
Senior Vice President of Technical Operations1.7yrsUS$666.79kgeen gegevens
Robert Kern
Chief Clinical Advisor3.7yrsgeen gegevensgeen gegevens
Gloria Cosgrove
Senior Vice President of Quality1.8yrsgeen gegevensgeen gegevens
Allison Nance
Senior Vice President of Regulatory Affairs1.8yrsgeen gegevensgeen gegevens
Elazer Edelman
VP of Finance & Riskno datageen gegevensgeen gegevens

2.2yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LYRA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Harlan Waksal
Executive Chairman2.7yrsUS$625.06k0.40%
$ 67.8k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79mgeen gegevens
James Tobin
Lead Independent Director2.6yrsUS$152.31k0%
$ 0
W. Smith
Independent Director4.9yrsUS$123.81k0%
$ 0
George Whitesides
Member of Scientific Advisory Board4yrsUS$333.93kgeen gegevens
C. Merrifield
Independent Director5.1yrsUS$113.06k0.017%
$ 2.9k
Robert Langer
Member of Scientific Advisory Board4yrsUS$19.36kgeen gegevens
Michael Dake
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
William Gray
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Mahmood Razavi
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
Gary Ansel
Member of Medical Advisory Boardno datageen gegevensgeen gegevens
I. Baumgartner
Member of Medical Advisory Boardno datageen gegevensgeen gegevens

4.0yrs

Gemiddelde duur

73yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LYRA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).